Prime time for ticagrelor monotherapy

Nature Reviews Cardiology, Published online: 14 October 2019; doi:10.1038/s41569-019-0300-4The TWILIGHT trial indicates that switching to ticagrelor monotherapy after 3 months of dual antiplatelet therapy lowers the incidence of bleeding without increasing ischaemic events compared with continuation of ticagrelor plus aspirin therapy in patients who have undergone percutaneous coronary intervention and are at high risk of bleeding or ischaemic events

Source: Nature Reviews Cardiology - October 13, 2019 Category: Cardiology Authors: Irene Fern ández-Ruiz Source Type: research